Tags

Type your tag names separated by a space and hit enter

The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
Psychiatry Res. 2012 Dec 30; 200(2-3):354-60.PR

Abstract

The effect of selective serotonin reuptake inhibitors (SSRI) on healthy individuals remains unclear. We tested the hypothesis that escitalopram decreases perceived stress and salivary cortisol. The trial has a randomised, blinded, placebo-controlled, parallel-group design. After informed consent 80 healthy first-degree relatives to patients with depression were randomly allocated to receive daily tablets of escitalopram 10mg or placebo for 4 weeks. The area under the curve (AUC) for awakening and all day salivary cortisol was analysed in samples taken immediately after awakening and at 15-min intervals for the next hour, and at 12:00, 18:00 and 23:00. The salivary cortisol awakening response, all day salivary cortisol, and scale scores on sleep, pain, aggression, quality of life, and perceived stress assessed at entry were compared to values following 4 weeks of intervention. Statistically significant decreases were found in awakening salivary cortisol (P=0.04) and in all day salivary cortisol (P=0.02) in the escitalopram group compared with the placebo group. There were no statistically significant differences in perceived stress between the intervention groups. These findings from a randomised clinical trial suggest that a long-term escitalopram administration to healthy participants results in a decrease in the hypothalamic-pituitary-adrenal (HPA) activity measured by salivary cortisol compared with inert placebo. However, change in salivary cortisol was one out of multiple outcome measures. The results of the present trial do not refute salivary cortisol as a potential endophenotype for depression.

Authors+Show Affiliations

Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen University Hospital, Denmark. ulla.knorr@regionh.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22703642

Citation

Knorr, Ulla, et al. "The Effect of Escitalopram Versus Placebo On Perceived Stress and Salivary Cortisol in Healthy First-degree Relatives of Patients With depression-A Randomised Trial." Psychiatry Research, vol. 200, no. 2-3, 2012, pp. 354-60.
Knorr U, Vinberg M, Gether U, et al. The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial. Psychiatry Res. 2012;200(2-3):354-60.
Knorr, U., Vinberg, M., Gether, U., Winkel, P., Gluud, C., Wetterslev, J., & Kessing, L. V. (2012). The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial. Psychiatry Research, 200(2-3), 354-60. https://doi.org/10.1016/j.psychres.2012.05.015
Knorr U, et al. The Effect of Escitalopram Versus Placebo On Perceived Stress and Salivary Cortisol in Healthy First-degree Relatives of Patients With depression-A Randomised Trial. Psychiatry Res. 2012 Dec 30;200(2-3):354-60. PubMed PMID: 22703642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial. AU - Knorr,Ulla, AU - Vinberg,Maj, AU - Gether,Ulrik, AU - Winkel,Per, AU - Gluud,Christian, AU - Wetterslev,Jørn, AU - Kessing,Lars Vedel, Y1 - 2012/06/14/ PY - 2011/04/13/received PY - 2012/05/14/revised PY - 2012/05/16/accepted PY - 2012/6/19/entrez PY - 2012/6/19/pubmed PY - 2013/5/18/medline SP - 354 EP - 60 JF - Psychiatry research JO - Psychiatry Res VL - 200 IS - 2-3 N2 - The effect of selective serotonin reuptake inhibitors (SSRI) on healthy individuals remains unclear. We tested the hypothesis that escitalopram decreases perceived stress and salivary cortisol. The trial has a randomised, blinded, placebo-controlled, parallel-group design. After informed consent 80 healthy first-degree relatives to patients with depression were randomly allocated to receive daily tablets of escitalopram 10mg or placebo for 4 weeks. The area under the curve (AUC) for awakening and all day salivary cortisol was analysed in samples taken immediately after awakening and at 15-min intervals for the next hour, and at 12:00, 18:00 and 23:00. The salivary cortisol awakening response, all day salivary cortisol, and scale scores on sleep, pain, aggression, quality of life, and perceived stress assessed at entry were compared to values following 4 weeks of intervention. Statistically significant decreases were found in awakening salivary cortisol (P=0.04) and in all day salivary cortisol (P=0.02) in the escitalopram group compared with the placebo group. There were no statistically significant differences in perceived stress between the intervention groups. These findings from a randomised clinical trial suggest that a long-term escitalopram administration to healthy participants results in a decrease in the hypothalamic-pituitary-adrenal (HPA) activity measured by salivary cortisol compared with inert placebo. However, change in salivary cortisol was one out of multiple outcome measures. The results of the present trial do not refute salivary cortisol as a potential endophenotype for depression. SN - 1872-7123 UR - https://www.unboundmedicine.com/medline/citation/22703642/The_effect_of_escitalopram_versus_placebo_on_perceived_stress_and_salivary_cortisol_in_healthy_first_degree_relatives_of_patients_with_depression_A_randomised_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-1781(12)00265-X DB - PRIME DP - Unbound Medicine ER -